Based on experience with similar medications from long-term follow-up studies, weight regains significantly within 6-12 months of stopping
Some practitioners recommend administering injections in the morning to align peak methyl donor availability with daytime metabolic activity, but clinical evidence supporting timing-specific benefits is limited
These activities are referenced within the peer-reviewed preclinical literature rather than as standalone pivotal-trial publications
According to the data provided by the Synapse Database, As of November 14, 2023, there are 37 investigational drugs for the GIPR and GLP-1R target, including 24 indications, 28 R&D institutions involved, with related clinical trials reaching 154, and as many as 1326 patents
Seufert J, Nauck M, Rosenstock J, Hansen T, Vrazic H, Vilsboll T